Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...
Revenue Guidance: Full-year Tecelra sales projected between $35 million and $45 million.
Net Sales for Q1 2025: $4 million from Tecelra treatments.
Tecelra Treatments Invoiced: 14 treatments in 2025 to date, with 6 in Q1.
Authorized Treatment Centers: 28 centers currently accepting referrals, with a target of approximately 30 by the end of 2025.
Manufacturing Success Rate: 100% success from the US Tecelra manufacturing center.
Average Turnaround Time: 27 days from apheresis to release, beating the target of 30 days.
Peak Sales Projection: $400 million from combined Tecelra and Lete-cel sarcoma franchise.
Warning! GuruFocus has detected 4 Warning Signs with ADAP.
Release Date: May 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) reported strong momentum with the launch of Tecelra, achieving $4 million in net sales for Q1 2025.
The company has successfully apheresed 21 patients in 2025, with 13 in Q1 and 8 in early Q2, supporting their revenue guidance of $35 million to $45 million for the year.
Adaptimmune has established 28 authorized treatment centers (ATCs) for Tecelra, with plans to reach 30 by the end of 2025, a year ahead of schedule.
The manufacturing success rate for Tecelra has been 100%, with no capacity issues and an average turnaround time of 27 days, beating the target of 30 days.
There have been no patient denials for Tecelra, indicating effective patient access and a positive payer environment.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has a going concern warning, indicating less than 12 months of cash runway, which raises concerns about financial sustainability.
The company has not provided detailed cash runway guidance due to various impacting factors, including the success of Tecelra's launch and ongoing cost reduction actions.
The cost of goods sold (COGS) is expected to be higher in the initial quarters, affecting margins, although they are projected to normalize over time.
There is uncertainty regarding the impact of potential regulatory changes on the business, although the company has not seen any negative indications from the FDA.
The company is still exploring strategic options with Cowen, which could imply potential changes or uncertainties in their strategic direction.
Q: Can you clarify if the apheresed patients in Q1 have already been treated and invoiced? A: Cintia Piccina, Chief Commercial Officer, explained that of the 21 apheresed patients year-to-date, at least six have been invoiced, with the majority expected to be invoiced in the coming months.
Q: Should we expect an acceleration in the number of apheresed patients in Q2? A: Adrian Rawcliffe, CEO, stated that while they are comfortable with the sales guidance of $35 million to $45 million for 2025, they are not providing detailed quarterly breakdowns of apheresis numbers.
Q: How has the pace of patient referrals and screening been trending, and do you expect incremental growth? A: Cintia Piccina noted that they expect quarter-over-quarter growth without specific seasonality, driven by increased awareness and the onboarding of more Authorized Treatment Centers (ATCs).
Q: What are the key learnings from the early launch of Tecelra? A: Cintia Piccina highlighted the faster-than-expected onboarding of treatment centers and the 100% manufacturing success rate as positive surprises, with patient onboarding and biomarker testing proceeding smoothly.
Q: How is the company managing its cash position and what are the implications of the recent debt paydown? A: Gavin Wood, CFO, explained that the debt paydown was part of managing the balance sheet and did not impact cash runway. The company has less than 12 months of cash, with ongoing strategic options being explored.
Q: What gives you confidence in providing revenue guidance for the year? A: Adrian Rawcliffe mentioned the visibility into the patient funnel, successful manufacturing, and the increasing number of ATCs as factors supporting the $35 million to $45 million revenue guidance.
Q: What is the drop-off rate for patients from apheresis to infusion? A: Adrian Rawcliffe confirmed that so far, 100% of apheresed patients have received infusions.
Q: Are there any planned manufacturing maintenance activities this year? A: John Lunger, Chief Patient Supply Officer, stated that maintenance is conducted on a rolling basis without impacting capacity, and no significant shutdowns are planned for the year.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
29-05-2025
- Hamilton Spectator
Grande Prairie disability advocates frustrated with province
Inclusion Grande Prairie held a town hall on Saturday to hear concerns regarding changes to the province's funding for people with disabilities. The two chairs reserved for local MLAs remained empty. 'It's so important to have a loud voice when speaking with this government because they have a tendency to ignore most of us,' said Keith Moore, Inclusion Grande Prairie president. Underfunding for disability programs, access to funds, upcoming AISH changes with the new Alberta Disability Assistance Program, and the province 'clawing back' the federal Canada Disability Benefit from individuals were among issues raised at the public event. The province is introducing the Alberta Disability Assistance Program (ADAP) expected to begin in July next year, but locals say there is not enough information for those who will be able to use it. 'We don't know what that new support level would be because there's just no information, and we have asked repeatedly,' said Moore. 'The trends with this government seem to be, let's just cut and cut and cut, people who are more vulnerable in our society are the ones that are targeted.' The province says ADAP will allow people with disabilities to pursue jobs while receiving the financial, medical, and personal support they need. It says ADAP will work alongside the current Assured Income for the Severely Handicapped (AISH) program. 'ADAP is going to be a lower monthly support but allow people to earn more income without it being deducted off their support,' said Moore. Currently, those on AISH have deductions from their monthly living allowance if they have income. Moore said currently AISH clients receive about $1,900 per month for food, rent and utilities. He noted the poverty line is about $2,400 a month in Edmonton. The Canada Disability Benefit (CBD) which could provide up to $200 a month was expected to help those with disabilities have more access to funds, but in Alberta CBD may add more barriers. Inclusion Alberta said in a media release that the province is requiring people on AISH to apply for the CBD but will then reduce their AISH payment by the received CBD amount. It says no other province is doing this. 'The CDB is meant to be a top-up, not a replacement for provincial disability income support,' said Trish Bowman, Inclusion Alberta CEO. 'Taking away a benefit that was intended to help reduce poverty for adults with disabilities is beyond comprehension.' About 77,000 Albertans are accessing AISH. The CBD has a $250 application fee, and approved clients need to qualify for the Disability Tax Credit that requires a medical assessment that may also come with a cost. 'It doesn't make sense,' shouted a person from the crowd at the town hall. Family Support for Children with Disabilities (FSCD) and Persons with Developmental Disabilities (PDD) funding is also underfunded, says Moore. He cited the latest publicly available annual report from the Advocate for Persons with Disabilities (2022-23). 'The budget for 2025 did add some money in, but it didn't even keep up with inflation or the population growth,' he said. 'Every year, we're falling further and further behind, and that is basically what the advocates report for 2022 says — insufficient funds.' People at the town hall voiced their frustrations with a system some called 'dehumanizing.' Moore says he sent invites to Grande Prairie MLA Nolan Dyck and Grande Prairie-Wapiti MLA Ron Wiebe. 'We're going to present everything that was brought forward by families,' said Moore, 'we're going to get folks to write out their stories and everything and will go to the MLAs and again, requesting them specifically to respond to us.' 'We expect them to do their job as allies represent us; they were not elected to represent Premier Smith or the caucus,' said Moore. Moore says contact with the local MLAs has been difficult. 'They're not very accommodating for people who want to meet with them,' he said, noting the MLA offices indicated that they limit meetings to a maximum of 30 minutes, won't meet after 7 p.m. and won't meet with more than six people at a time. Giving each person five minutes isn't long enough to illustrate how funding is affecting a person, he said. Moore, who served on the board of the Inclusion Alberta until last month, said there was no consultation done regarding AISH or the upcoming changes with ADAP. He said he wanted to see Inclusion Alberta included in the changes to legislation, noting the organization represents families across Alberta and that Inclusion Grande Prairie represents many people in northwestern Alberta from Edson to LaCrete. He said it's not uncommon for the province to include stakeholders before making changes to legislation noting oil and gas companies were included in legislative changes to abandoned wellsites. In March, the Family Resource Centre in Grande Prairie was closed after provincial funding cuts. 'When we lost the Family Resource Centre, one of the responses from the province was, we do not fund advocacy we fund supports,' said Moore. 'We helped over 200 families, during the time it was operational, find a way around the community, connect them with supporting organizations within the community, help guide them through inclusive education.' He said that parents don't know how to navigate the system. The centre helped them navigate funding, ensuring their children received proper education and aid and parents got the education they needed. 'The interesting thing is that the (Persons with Developmental Disabilities) PDD office in Grande Prairie often referred people to us,' he said, 'that's basically because the PDD office is understaffed; they're maybe 50 per cent of what they were five years ago, in numbers.' Funding to the Family Resource Centre was cut from about $120,000 a year to $64,000, said Moore. He said the province has also stipulated the centre would need to provide courses that follow 'provincial scripts' every month, that would include provincial audits for compliance. Moore said after some conversations, the province indicated it is still funding the Office of the Advocate for Persons with Disabilities. The website stated that the office would visit communities and talk to organizations. 'I invited them to come out to Grande Prairie to talk with (Inclusion Grande Prairie), also the Autism Society - because they're in the same boat we are - and two weeks later, I got a phone call and the lady said they were unable to come out because they didn't know what their budget was and couldn't travel.' Moore then asked if they could accommodate a Zoom meeting and was told it would need to be before 7 p.m. Town & Country News reached out to the Ministry of Assisted Living and Social Services but did not receive a response before press time.
Yahoo
28-05-2025
- Yahoo
CARsgen's Satri-cel Granted Priority Review by the NMPA
SHANGHAI, May 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Priority Review to satricabtagene autoleucel ("satri-cel", CT041)(an autologous CAR T-cell product candidate against protein Claudin18.2), for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. View original content to download multimedia: SOURCE CARsgen Therapeutics Sign in to access your portfolio
Yahoo
25-05-2025
- Yahoo
1 Stock Down 97% That Could Double, According to Wall Street
Editas Medicine focuses on developing gene-editing treatments. The struggling biotech recently gave up on its leading pipeline candidate. Even if it matches Wall Street's estimates in the next year, the stock is too risky. 10 stocks we like better than Editas Medicine › Over the past few years, investors have moved away from somewhat speculative and unprofitable companies to put their money into safer, steadier investments. Editas Medicine (NASDAQ: EDIT), a gene-editing-focused clinical-stage biotech, is firmly in the speculative camp, which is why its shares are down by 97% since early 2021. The stock is trading for about $1.50 right now. However, its average price target of $3.38 (according to Yahoo! Finance) implies a potential upside of about 125%. Should investors scoop up the company's shares expecting them to soar? Developing and marketing gene-editing therapies is challenging, as Editas Medicine knows well. The company's previous leading program was called reni-cel. It was being tested as a potential treatment for two rare blood disorders: sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Here is the problem: Ex vivo gene-editing therapies are complex to administer. The process requires collecting patients' cells, editing them, and reinserting them into the patients. Even going through the clinical trial phase for a treatment of this kind is more expensive than if it were a simple oral pill. Though reni-cel was making progress and showing strong signs of efficacy with the patients who had received treatment, Editas Medicine decided to discontinue its development because it couldn't find a commercial partner with big pockets. Even before that, though, Editas Medicine was fighting an uphill battle. Between 2022 and 2023, three gene-editing therapies were approved in the U.S.: Zynteglo, Lyfgenia, and Casgevy. Zynteglo and Lyfgenia treated TDT and SCD, respectively, while Casgevy targeted both. Editas Medicine's relatively slow progress with reni-cel didn't bode well with investors, considering there were already competing therapies on the market. The company's decision to discontinue this program was the right one -- the move hardly makes the stock particularly attractive, but trying to push reni-cel toward commercialization despite its slow progress and the competitive landscape would have been prohibitively expensive. Editas Medicine has decided to pivot toward developing in vivo gene-editing therapies. Unlike the ex vivo variety, these kinds are administered via injection into the body of therapeutic genes -- so there is no need to collect the patients' cells. Editas Medicine has partners for some of its in vivo programs. It is working on some medicines with Bristol Myers Squibb, a leading pharmaceutical company. Further, Editas Medicine has decreased expenses and costs thanks to discontinuing the development of reni-cel and laying off a sizable portion of its workforce. It expects its cash and equivalents balance of $221 million as of the end of the first quarter to keep it afloat until the second quarter of 2027. With a stock price of $1.50, it wouldn't be too surprising to see this company more than double in value in the next year, perhaps because of progress with an early-stage clinical program, or licensing deals for one of its medicines, or buyout interest from a larger drugmaker. However, Editas Medicine is far too risky a stock for long-term investors. Its current candidates haven't even started human clinical trials yet. It will be years before any get close to approval. It's also worth pointing out that Editas Medicine gave up the development of EDIT-101 and EDIT-103, two potential gene-editing therapies for various eye diseases, also because it failed to find a commercial partner. Given the biotech's poor track record and the current state of its operations, investing in the stock right now and expecting it to generate strong returns over the long run wouldn't be that different from gambling. Before you buy stock in Editas Medicine, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Editas Medicine wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!* Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool recommends Editas Medicine. The Motley Fool has a disclosure policy. 1 Stock Down 97% That Could Double, According to Wall Street was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
